磁共振弹性成像
脂肪性肝炎
医学
瞬态弹性成像
弹性成像
磁共振成像
纤维化
接收机工作特性
前瞻性队列研究
阶段(地层学)
肝纤维化
胃肠病学
放射科
内科学
诊断准确性
肝硬化
病理
生物标志物
曲线下面积
试验预测值
脂肪肝
超声科
吲哚青绿
肝纤维化
敏捷软件开发
医学影像学
门脉高压
作者
Michael Pavlides,Yasaman Vali,Ferenc Emil Mózes,Kristy Wonders,Salma Akhtar,Paul D. Hockings,Elizabeth Shumbayawonda,Kay Pepin,Isabel Fernández-Lizaranzu,Diana Julie Leeming,Jeremy Cobbold,Michael E. Allison,Guruprasad Padur Aithal,Manuel Romero‐Gómez,Rocio Aller,Juan Manuel Pericàs,Jérôme Boursier,Salvatore Petta,Jörn Markus Schattenberg,Mattias Ekstedt
出处
期刊:Nature Medicine
[Nature Portfolio]
日期:2026-07-24
卷期号:32 (8): 2959-2969
被引量:12
标识
DOI:10.1038/s41591-026-04496-2
摘要
There is a need for robust evaluations of noninvasive biomarkers for metabolic dysfunction-associated steatotic liver disease. This prospective multicenter study assessed the diagnostic accuracy of imaging (including liver stiffness measurement (LSM) using magnetic resonance elastography (MRE) and FibroScan (vibration-controlled transient elastography (VCTE)), serum biomarkers (including NIS2+) and composite scores (including Agile 3+ and Agile 4) for centrally read steatohepatitis and fibrosis. For cirrhosis, several biomarkers exceeded the minimum acceptable performance criterion (MAC), including MRE (area under the receiver operating curve (AUC) 0.91; P < 0.01), VCTE-LSM (AUC 0.87; P < 0.01), Agile 3+ (AUC 0.89; P < 0.01) and Agile 4 (AUC 0.88; P < 0.01). Among 357 participants, fibrosis stages F0-F4 were present in 12%, 16%, 25%, 32% and 15%, respectively. NIS2+ had the highest diagnostic accuracy among serum biomarkers for metabolic dysfunction-associated steatohepatitis (MASH; AUC 0.83) and at-risk MASH (MASH with at least stage 2 fibrosis; AUC 0.82), although neither significantly exceeded the MAC (P = 0.15 and P = 0.19). Among imaging biomarkers, MRE showed the highest performance for MASH (AUC 0.71) and at-risk MASH (AUC 0.75), but these remained below the MAC. For fibrosis staging, performance was stronger: MRE met the MAC for advanced fibrosis (AUC 0.91; P < 0.01), as did Agile 3+ (AUC 0.84; P = 0.03). For cirrhosis, several biomarkers exceeded the MAC, including MRE (AUC 0.91; P < 0.01), VCTE-LSM (AUC 0.87; P < 0.01), Agile 3+ (AUC 0.89; P < 0.01) and Agile 4 (AUC 0.88; P < 0.01). Serum biomarkers tended to outperform imaging for identifying at-risk MASH, whereas elastography and composite scores showed excellent accuracy for staging advanced fibrosis and cirrhosis.
科研通智能强力驱动
Strongly Powered by AbleSci AI